Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS)   JANUARY 2011 , Volume 16 , Number 1; Page(s) 1 To 5.
 
Paper: 

Mycophenolate Mofetil In Combination With Interferon Beta-1A In The Treatment Of Relapsing-Remitting Multiple Sclerosis: A Preliminary Study

 
 
Author(s):  Etemadifar Masoud, Kazemi Mojtaba*, Chitsaz Ahmad, Hekmatnia Ali, Tayari Nazila, Ghazavi Amirhossein, Maghzi Amir Hadi
 
* DEPARTMENT OF NEUROLOGY, SCHOOL OF MEDICINE, ISFAHAN UNIVERSITY OF MEDICAL SCIENCES, ISFAHAN, IRAN
 
Abstract: 
BACKGROUND: The efficacy of Mycophenolate mofetil (MMF) plus interferon beta-1a (IFNB-1a) in treatment of relapsing- remitting multiple sclerosis (RRMS) was evaluated.METHODS: This was a pilot study with randomized, double-blinded, placebo-controlled design. Patients with RRMS and Expanded Disability Status Scale score (EDSS) of < 6.0 were included. Those with relapse within the previous two months and prior use of immunomodulatory/immunosuppressive drugs were excluded. Patients were randomized into MMF (n=13) and placebo (n=13) groups and received weekly intramuscular IFNB-1a plus either MMF or placebo.MMF started by 500 mg/d for one week and weekly escalated by 500 mg/d, until target divided dose of 2000 mg/d and continued for 12 months. Radiologic and clinical assessments were performed at baseline and then at month 12.RESULTS: After one year of therapy, difference between the two groups in number of new T2 lesions was not statistically significant (0.54 ± 0.77 in MMF vs.1.85 ± 3.2 in placebo group, p=0.169) . Two patients in the placebo group had gadolinium-enhanced lesions and one patient had relapse. There were 3 patients in each group with more than one point progression in EDSS. Common side effect in the MMF group included gastrointestinal upset, but no patient discontinued the treatment.CONCLUSIONS: Combination of MMF with IFNB-1a in patients with RRMS is well tolerated, but the efficacy of such combination was not statistically significant in this pilot study and deserves further investigation with a larger sample size and a longer follow-up.
 
Keyword(s): MYCOPHENOLATE MOFETIL, INTERFERON BETA-1A, IMMUNOSUPPRESSIVE, RELAPSING-REMITTING MULTIPLE SCLEROSIS
 
 
International related papers: 
 
Most related Highly related Moderately related Least related
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

ETEMADIFAR, M., & KAZEMI, M., & CHITSAZ, A., & HEKMATNIA, A., & TAYARI, N., & GHAZAVI, A., & MAGHZI, A. (2011). MYCOPHENOLATE MOFETIL IN COMBINATION WITH INTERFERON BETA-1A IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: A PRELIMINARY STUDY. JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS), 16(1), 1-5. https://www.sid.ir/en/journal/ViewPaper.aspx?id=192724



Vancouver: Copy

ETEMADIFAR MASOUD, KAZEMI MOJTABA, CHITSAZ AHMAD, HEKMATNIA ALI, TAYARI NAZILA, GHAZAVI AMIRHOSSEIN, MAGHZI AMIR HADI. MYCOPHENOLATE MOFETIL IN COMBINATION WITH INTERFERON BETA-1A IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: A PRELIMINARY STUDY. JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS). 2011 [cited 2022January28];16(1):1-5. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=192724



IEEE: Copy

ETEMADIFAR, M., KAZEMI, M., CHITSAZ, A., HEKMATNIA, A., TAYARI, N., GHAZAVI, A., MAGHZI, A., 2011. MYCOPHENOLATE MOFETIL IN COMBINATION WITH INTERFERON BETA-1A IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: A PRELIMINARY STUDY. JOURNAL OF RESEARCH IN MEDICAL SCIENCES (JRMS), [online] 16(1), pp.1-5. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=192724.



 
  pdf-File
Yearly Visit 53
 
 
Latest on Blog
Enter SID Blog